Pfizer, Inc. — PFE

Close PriceMarket CapP/E RatioForward P/E RatioImplied Growth*Implied Forward Growth*DividendP/B Ratio
$24.43$138.90B14.28.37.7%2.3%$1.72
7.0%		1.5

Revenue & Net Income

Revenue & Net Income
  Date Revenue Net Income EPS Revenue Change Net Income Change EPS Change
0 2020-12-31 $41.7B $9.2B $1.73 N/A N/A N/A
1 2021-12-31 $81.3B $22.0B $3.92 95.2% 140.0% 126.6%
2 2022-12-31 $100.3B $31.4B $5.59 23.4% 42.7% 42.6%
3 2023-12-31 $58.5B $2.1B $0.38 -41.7% -93.2% -93.2%
4 2024-12-31 $63.6B $8.0B $0.38 8.8% 279.0% 0.0%
5 TTM 2025-03-31 $62.5B $7.9B $1.38 -1.8% -1.8% 263.2%
6 Average 16.8% 73.3% 67.8%

EPS

EPS

Forecasts

Revenue/Net Income Forecast EPS Forecast

Y/Y % Change

Revenue YoY Change EPS YoY Change
YoY Growth Rates

PFE Year-over-Year Growth

  2020 2021 2022 2023 2024 2025 2026 Average
Revenue Growth (%) 95.2% 23.4% -41.7% 8.8% -1.0% -1.1% 13.9%
Revenue Analysts (#) 0 0 0 0 0 4 4
EPS Growth (%) 140.0% 42.7% -93.2% 279.0% 121.6% 0.3% 81.7%
EPS Analysts (#) 0 0 0 0 0 4 4

Expenses

Revenue vs Expenses Expenses % of Revenue
Year Revenue ($) Cost of Revenue ($) R&D ($) SG&A ($) Facilities / D&A ($)
2021 $81.3B $24.1B $13.8B $12.7B $5.2B
2022 $101.2B $27.8B $12.4B $13.7B $5.1B
2023 $59.6B $17.1B $10.9B $14.8B $6.3B
2024 $63.6B $9.1B $10.9B $14.7B $7.0B
TTM $63.8B $9.3B $10.4B $14.0B $6.8B
Year Revenue Change (%) Cost of Revenue Change (%) R&D Change (%) SG&A Change (%) Facilities / D&A Change (%)
2022 24.46 15.27 -10.47 7.67 -2.45
2023 -41.14 -38.52 -12.18 8.00 24.21
2024 6.84 -46.74 0.52 -0.28 11.49
TTM 0.32 2.18 -4.57 -5.20 -3.19
No unmapped expenses.

Segment Performance

axis1_PFE_Paxlovid_N_D_A_Labeled_U_S_Strategic_National_Stockpile.png
axis1_PFE_Product.png
axis1_PFE_Royalty.png
SEGMENTS v2025-09-09 · 2025-11-10 08:28 UTC — Units: $B. Rows list fiscal years (last 3 + TTM) with revenue and operating income for each segment; the final row shows the TTM revenue mix (operating income columns display “—” where mix is not applicable).
Year Prod Rev Prod OI Royalty Rev Royalty OI Paxlovid N D A Labeled U S Strategic National Stockpile Rev Paxlovid N D A Labeled U S Strategic National Stockpile OI Total Rev Total OI
2022 92.2B 0.00B 2.30B 0.00B – – 94.5B 0.00B
2023 51.1B 0.00B 2.72B 0.00B – – 53.8B 0.00B
2024 54B 0.00B 3.77B 0.00B 1.33B 0.00B 59.1B 0.00B
TTM 105.1B 0.00B 6.98B 0.00B 0.44B 0.00B 112.5B 0.00B
% of Total (TTM) 93.4% — 6.2% — 0.4% — 100% —

Balance Sheet

Balance Sheet
  Metric Value
0 Total Assets $206,095M
1 Cash $1,638M
2 Total Liabilities $117,083M
3 Total Debt $60,926M
4 Total Equity $88,695M
5 Debt to Equity Ratio 0.69

EPS & Dividend

EPS & Dividend

Valuation

Valuation
Share Price Treasury Yield Estimates Fair Value (P/E) Fair Value (P/S) Current P/S Current P/E
$23.97 4.4% Nicks Growth: 2%
Nick's Expected Margin: 10%
FINVIZ Growth: -0%		 Nicks: 8
Finviz: 6		 Nick's: 0.786 2.2 17.4
Basis Year Nicks Valuation Nicks vs Share Price Finviz Valuation Finviz vs Share Price
$1.38 EPS TTM $10.85 -54.7% $8.58 -64.2%
$3.06 EPS 2025 $24.06 0.4% $19.02 -20.7%
$3.09 EPS 2026 $24.30 1.4% $19.20 -19.9%

Implied Growth

Implied Growth
Average Median Std Dev Current Percentile
TTM Forward TTM Forward TTM Forward TTM Forward TTM Forward
Timeframe
1 Year 7.98% 2.53% 7.02% 2.46% 1.66% 0.34% 7.66% 2.29% 64.8% 28.7%
3 Years 7.98% 2.53% 7.02% 2.46% 1.66% 0.34% 7.66% 2.29% 64.8% 28.7%
5 Years 7.98% 2.53% 7.02% 2.46% 1.66% 0.34% 7.66% 2.29% 64.8% 28.7%
10 Years 7.98% 2.53% 7.02% 2.46% 1.66% 0.34% 7.66% 2.29% 64.8% 28.7%

← Back